Sign In
Buy VKTX
$38.86
-2.28 (-5.54%)
At Close: Jul 10, 2026
Facebook, Spotify, Wingstop and More Thursday Afternoon Analyst Upgrades and Downgrades
12:33pm, Thursday, 29'th Jul 2021
Shares were higher across the board as we reached the midway point for Thursday trading.
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript
09:27pm, Wednesday, 28'th Jul 2021
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 28'th Jul 2021
SAN DIEGO, July 28, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021
04:05pm, Wednesday, 21'st Jul 2021
SAN DIEGO, July 21, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
07:05am, Thursday, 24'th Jun 2021
SAN DIEGO, June 24, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
07:05am, Thursday, 17'th Jun 2021
SAN DIEGO, June 17, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Viking Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 10'th Jun 2021
SAN DIEGO, Calif., June 10, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for meta
10 Cheap Stocks Under $10 the Pros Are Buying
02:15pm, Friday, 21'st May 2021
If you're looking for a cheap stock to buy, check out this list of 10 highly rated picks that are priced under $10.
Viking Therapeutics: Checking For A Pulse
08:31am, Wednesday, 19'th May 2021
Viking Therapeutics recently reported their Q1 earnings that revealed the company still has a strong cash position to help fund their impressive pipeline of metabolic and endocrine therapeutic candida
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2021 Results - Earnings Call Transcript
09:41pm, Wednesday, 28'th Apr 2021
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2021 Results - Earnings Call Transcript
Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
04:05pm, Wednesday, 21'st Apr 2021
SAN DIEGO, April 21, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a
Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 07'th Apr 2021
SAN DIEGO, April 7, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an
Viking Therapeutics' (VKTX) CEO Brian Lian on Q4 2020 Results - Earnings Call Transcript
08:33pm, Wednesday, 17'th Feb 2021
Viking Therapeutics' (VKTX) CEO Brian Lian on Q4 2020 Results - Earnings Call Transcript
Viking Therapeutics Announces Senior Management Team Appointments
04:05pm, Wednesday, 06'th Jan 2021
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Viking Therapeutics: Progressing Steadily, But Concerns Remain
07:09am, Sunday, 29'th Nov 2020
The entire NASH space was shaken by Genfit's trial fiasco; Viking has its own problems. The drug may actually be a wonderful new therapy for NASH/NAFLD patients; however, whether VKTX will benefit fro
